FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Legacy Pharmaceutical Packaging Losartan Potassium Tablets Recall

Losartan Potassium Tablets, USP, 50 mg, 30 tablet bottles, Rx Only, Distributed by: Wal…

Legacy Pharmaceutical Packaging LLC · Earth City, MO

Risk level
Class II
Reported by FDA
Mar 27, 2019
Recall ID
D-1049-2019
Check your lot numberHow we source this data

Summary

Legacy Pharmaceutical Packaging recalled Losartan Potassium Tablets starting Mar 1, 2019. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1049-2019 on Mar 27, 2019. Reason: CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected. Status: Ongoing.

Why it was recalled

CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected

Product description

Losartan Potassium Tablets, USP, 50 mg, 30 tablet bottles, Rx Only, Distributed by: Wal-Mart, Bentonville, AR 72716, Manufactured for: Camber Pharmaceuticals, Inc. Piscataway, NJ 08854, Packaged by: Legacy Pharmaceutical Packaging LLC, Earth City, MO 63045. NDC 68645-578-54

Lot numbers, UPCs & expiration codes

Lots: 180921, exp Sep-19, 180922, exp Oct-19, 180923, 180924, 181118, exp Nov-19, 181119, exp Oct-19, 181407, exp Nov-19, 181408, exp Dec-19, 181573, 181725, 181726, exp Feb-20, 181948, exp Mar-20, 181960, exp Feb-20, 182385, 182386, 182387, exp Mar-20

Where it was sold

Wal-Mart distribution centers in AR, CA, GA, IN and MD

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1049-2019
Classification
Class II
Status
Ongoing
Recall initiated
Mar 1, 2019
FDA report date
Mar 27, 2019
Quantity
2,851,284 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Legacy Pharmaceutical Packaging LLC

Original FDA data

Every field from FDA enforcement report D-1049-2019, exactly as published.

Show all FDA fields
City
Earth City
State
MO
Status
Ongoing
Country
United States
Event ID
82326
Address
13333 Lakefront Dr
Code information
Lots: 180921, exp Sep-19, 180922, exp Oct-19, 180923, 180924, 181118, exp Nov-19, 181119, exp Oct-19, 181407, exp Nov-19, 181408, exp Dec-19, 181573, 181725, 181726, exp Feb-20, 181948, exp Mar-20, 181960, exp Feb-20, 182385, 182386, 182387, exp Mar-20
Postal code
63045-1514
Report date
Mar 27, 2019
Product type
Drugs
Recall number
D-1049-2019
Classification
Class II
Recalling firm
Legacy Pharmaceutical Packaging LLC
Product quantity
2,851,284 bottles
Reason for recall
CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected
Voluntary / mandated
Voluntary: Firm initiated
Product description
Losartan Potassium Tablets, USP, 50 mg, 30 tablet bottles, Rx Only, Distributed by: Wal-Mart, Bentonville, AR 72716, Manufactured for: Camber Pharmaceuticals, Inc. Piscataway, NJ 08854, Packaged by: Legacy Pharmaceutical Packaging LLC, Earth City, MO 63045. NDC 68645-578-54
Distribution pattern
Wal-Mart distribution centers in AR, CA, GA, IN and MD
Recall initiation date
Mar 1, 2019
Initial firm notification
Letter
Center classification date
Mar 21, 2019

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1049-2019, published Mar 27, 2019. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls